Short Interest in Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Declines By 97.0%

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) was the recipient of a significant decline in short interest during the month of July. As of July 31st, there was short interest totaling 16,980 shares, a decline of 97.0% from the July 15th total of 569,675 shares. Currently, 1.7% of the company’s stock are sold short. Based on an average daily trading volume, of 555,531 shares, the days-to-cover ratio is currently 0.0 days.

Insiders Place Their Bets

In other Bluejay Diagnostics news, major shareholder Financial Lp Hrt sold 34,938 shares of the company’s stock in a transaction that occurred on Friday, July 10th. The stock was sold at an average price of $1.40, for a total transaction of $48,913.20. Following the sale, the insider owned 92,055 shares in the company, valued at $128,877. This represents a 27.51% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. 6.10% of the stock is currently owned by corporate insiders.

Institutional Trading of Bluejay Diagnostics

A hedge fund recently bought a new stake in Bluejay Diagnostics stock. Armistice Capital LLC purchased a new position in Bluejay Diagnostics, Inc. (NASDAQ:BJDX) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 65,000 shares of the company’s stock, valued at approximately $43,000. Armistice Capital LLC owned about 9.15% of Bluejay Diagnostics at the end of the most recent quarter. 18.47% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Bluejay Diagnostics in a report on Wednesday, June 24th. Wall Street Zen upgraded Bluejay Diagnostics to a “sell” rating in a research note on Saturday, July 18th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has an average rating of “Sell”.

Bluejay Diagnostics Stock Up 8.4%

BJDX opened at $1.07 on Wednesday. The firm has a market cap of $1.10 million, a price-to-earnings ratio of -0.09 and a beta of 0.89. Bluejay Diagnostics has a fifty-two week low of $0.83 and a fifty-two week high of $16.68. The company’s 50-day moving average price is $2.31 and its 200 day moving average price is $2.24.

Bluejay Diagnostics Company Profile

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.